| Business Summary | | Abbott
Laboratories
engages
in
the
discovery,
development,
manufacture
and
sale
of
a
broad
and
diversified
line
of
healthcare
products
and
services.
Abbott
has
five
business
segments:
Pharmaceutical
Products,
Diagnostic
Products,
Hospital
Products,
Ross
Products
and
International.
Abbott
also
owns
50%
of
a
joint
venture,
TAP
Pharmaceutical
Products
Inc.
On
December
15,
2000,
Abbott
announced
that
it
has
a
definitive
agreement
with
BASF,
A.G.
to
acquire
the
pharmaceutical
business
of
BASF,
which
includes
the
global
pharmaceutical
operations
of
Knoll. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | ABT
is
engaged
in
the
discovery,
development,
manufacture
and
sale
of
a
broad
line
of
health
care
products
and
services,
including
diagnostic,
pharmaceutical
and
hospital
products.
For
the
six
months
ended
6/01,
sales
rose
14%
to
$7.66
billion.
Net
income
fell
78%
to
$305.4
million.
Revenues
reflect
higher
unit
sales
in
the
Hospital
and
Pharmaceutical
segments.
Earnings
suffered
from
a
$1.19
billion
charge
for
the
acquisition
of
the
pharmaceutical
business
of
BASF. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Miles White, 45 Chairman
and Chief Exec. Officers | $3.3M | $230K | Thomas Freyman, 46 CFO,
Sr. VP | -- | -- | Jeffrey Leiden, M.D., Ph.D., 45 Exec.
VP of Pharmaceuticals and CHief Scientific Officer, Director | -- | -- | Richard Gonzalez, 47 Exec.
VP, Medical Products | 1.8M | 716K | Jose De Lasa, 59 Sr.
VP, Sec. and Gen. Counsel | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|